Background Advancements in sequencing technologies have led to useful molecular classifications of breast cancer—specifically HER2, Basal-Like, Luminal-A, and Luminal-B classifications of the Prosigna PAM50 qPCR assay. These classifications allow a better prediction of disease outcome and have led to the development of more class-specific therapies. Towards a better understanding of the “proteo-genomic” relationship between somatic mutation and signaling in breast cancer, recent quantitative proteomic analyses suggest that breast-cancer may be subdivided into three, rather than four, distinct subgroups—Stromal, Luminal, and Basal. This opens the door for developing therapies based on the aberrant protein signaling of the tumor, especially f...
International audienceThe current histoclinical breast cancer classification is simple but imprecise...
International audienceBackgroundBreast cancer is a heterogeneous disease with a wide range of outcom...
International audienceThe current histoclinical breast cancer classification is simple but imprecise...
Background: Breast cancer is a complex and heterogeneous disease that is usually characterized by hi...
Background: Breast cancer is a complex and heterogeneous disease that is usually characterized by hi...
The utilization of high-throughput -omics strategies, such as proteomics, in the analysis of breastc...
Systems-wide profiling of breast cancer has almost always entailed RNA and DNA analysis by microarra...
The exponentially increasing volume of information extracted from genomic and proteomic applications...
Systems-wide profiling of breast cancer has almost always entailed RNA and DNA analysis by microa...
Background: Breast cancer is a complex and heterogeneous disease that is usually characterized by hi...
The exponentially increasing volume of information extracted from genomic and proteomic applications...
In the preceding decades, molecular characterization has revolutionized breast cancer (BC) research ...
In the preceding decades, molecular characterization has revolutionized breast cancer (BC) research ...
International audienceThe current histoclinical breast cancer classification is simple but imprecise...
International audienceBackgroundBreast cancer is a heterogeneous disease with a wide range of outcom...
International audienceThe current histoclinical breast cancer classification is simple but imprecise...
International audienceBackgroundBreast cancer is a heterogeneous disease with a wide range of outcom...
International audienceThe current histoclinical breast cancer classification is simple but imprecise...
Background: Breast cancer is a complex and heterogeneous disease that is usually characterized by hi...
Background: Breast cancer is a complex and heterogeneous disease that is usually characterized by hi...
The utilization of high-throughput -omics strategies, such as proteomics, in the analysis of breastc...
Systems-wide profiling of breast cancer has almost always entailed RNA and DNA analysis by microarra...
The exponentially increasing volume of information extracted from genomic and proteomic applications...
Systems-wide profiling of breast cancer has almost always entailed RNA and DNA analysis by microa...
Background: Breast cancer is a complex and heterogeneous disease that is usually characterized by hi...
The exponentially increasing volume of information extracted from genomic and proteomic applications...
In the preceding decades, molecular characterization has revolutionized breast cancer (BC) research ...
In the preceding decades, molecular characterization has revolutionized breast cancer (BC) research ...
International audienceThe current histoclinical breast cancer classification is simple but imprecise...
International audienceBackgroundBreast cancer is a heterogeneous disease with a wide range of outcom...
International audienceThe current histoclinical breast cancer classification is simple but imprecise...
International audienceBackgroundBreast cancer is a heterogeneous disease with a wide range of outcom...
International audienceThe current histoclinical breast cancer classification is simple but imprecise...